Institutional members access full text with Ovid®

New Drug for Type 2 Diabetes

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: September 2011 - Volume 111 - Issue 9 - pp 22-23
doi: 10.1097/01.NAJ.0000405054.38571.4f
Drug Watch

* Linagliptin (Tradjenta) is the newest drug approved for type 2 diabetes.

* Linagliptin promotes the function of endogenous incretins, hormones that work to lower elevated blood glucose levels.

* The drug doesn't usually cause hypoglycemia and is generally well tolerated.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2011 Lippincott Williams & Wilkins, Inc.